These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Glass Leachables as a Nucleation Factor for Free Fatty Acid Particle Formation in Biopharmaceutical Formulations. Allmendinger A; Lebouc V; Bonati L; Woehr A; Kishore RSK; Abstiens K J Pharm Sci; 2021 Feb; 110(2):785-795. PubMed ID: 33035535 [TBL] [Abstract][Full Text] [Related]
10. Polysorbate 20 Degradation in Biopharmaceutical Formulations: Quantification of Free Fatty Acids, Characterization of Particulates, and Insights into the Degradation Mechanism. Tomlinson A; Demeule B; Lin B; Yadav S Mol Pharm; 2015 Nov; 12(11):3805-15. PubMed ID: 26419339 [TBL] [Abstract][Full Text] [Related]
11. How enzymatic hydrolysis of polysorbate 20 influences colloidal protein stability. Glücklich N; Carle S; Diederichs T; Buske J; Mäder K; Garidel P Eur J Pharm Sci; 2023 Dec; 191():106597. PubMed ID: 37770006 [TBL] [Abstract][Full Text] [Related]
12. Dissolution of Polysorbate 20 Degradation Related Free Fatty Acid Particles in Intravenous Bag Solutions. Doshi N; Rutherford K; Najjar A J Pharm Sci; 2021 Feb; 110(2):687-692. PubMed ID: 33039438 [TBL] [Abstract][Full Text] [Related]
13. The Strengths of Total Holographic Video Microscopy in Detecting Sub-Visible Protein Particles in Biopharmaceuticals: A Comparison to Flow Imaging and Resonant Mass Measurement. Rahn H; Oeztuerk M; Hentze N; Junge F; Hollmann M J Pharm Sci; 2023 Apr; 112(4):985-990. PubMed ID: 36596393 [TBL] [Abstract][Full Text] [Related]
14. Extended Characterization and Impact of Visible Fatty Acid Particles - A Case Study With a mAb Product. Saggu M; Demeule B; Jiang L; Kammerer D; Nayak PK; Tai M; Xiao N; Tomlinson A J Pharm Sci; 2021 Mar; 110(3):1093-1102. PubMed ID: 33271136 [TBL] [Abstract][Full Text] [Related]
15. Combining Machine Learning and Backgrounded Membrane Imaging: A Case Study in Comparing and Classifying Different Types of Biopharmaceutically Relevant Particles. Calderon CP; Krhač Levačić A; Helbig C; Wuchner K; Menzen T J Pharm Sci; 2022 Sep; 111(9):2422-2434. PubMed ID: 35661758 [TBL] [Abstract][Full Text] [Related]
16. Polysorbate Degradation and Particle Formation in a High Concentration mAb: Formulation Strategies to Minimize Effect of Enzymatic Polysorbate Degradation. Roy I; Patel A; Kumar V; Nanda T; Assenberg R; Wuchner K; Amin K J Pharm Sci; 2021 Sep; 110(9):3313-3323. PubMed ID: 34077768 [TBL] [Abstract][Full Text] [Related]
17. Hydrolytic polysorbate 20 degradation - Sensitive detection of free fatty acids in biopharmaceuticals via UPLC-QDa analytics with isolator column. Evers DH; Carle S; Lakatos D; Hämmerling F; Garidel P; Buske J J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1174():122717. PubMed ID: 33975273 [TBL] [Abstract][Full Text] [Related]
18. Monitoring polysorbate hydrolysis in biopharmaceuticals using a QC-ready free fatty acid quantification method. Honemann MN; Wendler J; Graf T; Bathke A; Bell CH J Chromatogr B Analyt Technol Biomed Life Sci; 2019 May; 1116():1-8. PubMed ID: 30951966 [TBL] [Abstract][Full Text] [Related]
19. A Newly Identified Impurity in Polysorbate 80, the Long-Chain Ketone 12-Tricosanone, Forms Visible Particles in a Biopharmaceutical Drug Product. Hampl V; Guo X; Ehrenstrasser C; Viertler M; Rayner L; Campanelli G; Schipflinger R; Thewes K; Cerreti A; Boehm S; Sonderegger C J Pharm Sci; 2018 Jun; 107(6):1552-1561. PubMed ID: 29499279 [TBL] [Abstract][Full Text] [Related]
20. Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations. Zhang J; He J; Smith KJ J Pharm Sci; 2022 Mar; 111(3):655-662. PubMed ID: 34666046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]